FDAnews Device Daily Bulletin

FFR Benefit Prompts St. Jude to Halt FAME II Study

The sponsor of the FAME II trial, which is assessing the efficacy of fractional flow reserve (FFR) as a tool to improve stenting outcomes, said it is halting enrollment after an analysis revealed a significant benefit for patients in the FFR arm.
MedPage Today